In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda/ Millennium: The Price is Right

Executive Summary

Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
Advertisement

Related Content

Biogen Idec Taps Exelixis' Scangos To Be New CEO
Astellas Wins OSI But Victory Comes At A Price
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
Bristol-Myers Squibb and Otsuka Stabilize Their Bases
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Best of the Blog: IN VIVO, June 2008
Takeda's Global Ambition
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED
Millennium: The Risks of Forward Integration
Millennium: Genes Are Not Enough

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel